Christy Hawks
Family · Madison, NCNPI 1114310232
Payments from drug & device makers
Across 236 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$624
- Novo Nordisk$583
- AstraZeneca$522
- Lilly USA, LLC$329
- AbbVie$229
- Astellas Pharma US Inc$210
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,10398%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $624 |
| Novo Nordisk | 39 | $583 |
| AstraZeneca | 31 | $522 |
| Lilly USA, LLC | 20 | $329 |
| AbbVie | 16 | $229 |
| Astellas Pharma US Inc | 10 | $210 |
| Dexcom, Inc. | 6 | $164 |
| Amgen | 10 | $161 |
| Boehringer Ingelheim | 8 | $156 |
| Exact Sciences | 8 | $146 |
| Johnson & Johnson | 7 | $145 |
| GSK | 6 | $130 |
| Ironwood Pharmaceuticals, Inc | 5 | $106 |
| Pfizer | 7 | $103 |
| Phathom Pharmaceuticals, Inc. | 7 | $101 |
| Novartis | 4 | $83 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $29 |
| Merck | 2 | $29 |
| Cequr Corporation | 2 | $27 |
| Bayer | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,189 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 89 | $141,432 |
| OzempicSemaglutide | 101 | $130,343 |
| FarxigaDapagliflozin Propanediol | 82 | $93,110 |
| EliquisApixaban | 108 | $92,303 |
| JardianceEmpagliflozin | 87 | $91,929 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $72,799 |
| LinzessLinaclotide | 37 | $40,424 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $30,952 |
| RybelsusSemaglutide | 23 | $29,626 |
| MyrbetriqMirabegron | 49 | $26,785 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $22,657 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $21,748 |
| XareltoRivaroxaban | 13 | $20,383 |
| TrulicityDulaglutide | 15 | $17,461 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $583 | $159,969124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $329 | $158,893104 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $522 | $145,810190 claims |
| PfizerEliquis, Paxlovid | $103 | $95,046120 claims |
| Boehringer IngelheimJardiance | $156 | $91,92987 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $130 | $83,725109 claims |
| AbbVieLinzess | $229 | $40,42437 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $26,78549 claims |
| Johnson & JohnsonXarelto | $145 | $20,38313 claims |
| MerckLagevrio (Eua) | $29 | $8,63917 claims |
| Esperion Therapeutics, Inc.Nexlizet | $59 | $4,81212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Madison
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.